Zydus Lifesciences is currently trading at Rs. 982.30, up by 3.55 points or 0.36% from its previous closing of Rs. 978.75 on the BSE.
The scrip opened at Rs. 997.95 and has touched a high and low of Rs. 997.95 and Rs. 972.80 respectively. So far 55479 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1323.90 on 09-Aug-2024 and a 52 week low of Rs. 797.05 on 07-Apr-2025.
Last one week high and low of the scrip stood at Rs. 997.95 and Rs. 949.25 respectively. The current market cap of the company is Rs. 98314.09 crore.
The promoters holding in the company stood at 74.99%, while Institutions and Non-Institutions held 18.33% and 6.68% respectively.
Zydus Lifesciences has received the Establishment Inspection Report (EIR) from United States Food and Drug Administration (USFDA) for the inspection conducted at its API manufacturing facility located at Ankleshwar. This facility underwent an inspection from March 10, 2025 to March 14, 2025 and the inspection has been classified as No Action Indicated (NAI). The USFDA has concluded that this inspection is ‘closed’.
Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1693.15 |
| Dr. Reddys Lab | 1221.25 |
| Cipla | 1230.75 |
| Zydus Lifesciences | 939.20 |
| Lupin | 2326.50 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: